LorrinKYeeMD

PubMed

• 3 citations
  Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical ...
  Emiliano Calvo, Analia Azaro, Jordi Rodon, Luc Dirix, Manon T. Huizing, Francis Mark Senecal, Patricia LoRusso, Lorrin K. Yee, Italo Poggesi, Jan de Jong, Spyros Trian...> ;Investigational New Drugs. 2018 Jun 1
• 141 citations
  Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-l...
  Irene Brana, Antonio Calles, Patricia LoRusso, Lorrin K. Yee, Thomas A. Puchalski, Shobha Seetharam, Bob Zhong, Carla de Boer, Josep Tabernero, Emiliano Calvo> ;Targeted Oncology. 2015 Mar 1
• 47 citations
  TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
  Charles S. Fuchs, Lee S. Schwartzberg, Allen Lee Cohn, Lorrin Yee, Luke Dreisbach, Mark Kozloff, Y. J. Hei, Francesco Galimi, Yang Pan, Vincent Haddad, Cheng-Pang Hsu,...> ;Cancer. 2013 Dec 15
• 69 citations
  Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
  Patricia LoRusso, Pasi A. Jänne, Moacyr Ribeiro de Oliveira, Naiyer A. Rizvi, Lisa Malburg, Vicki L. Keedy, Lorrin K. Yee, Catherine Copigneaux, Thore Hettmann, Chi-Yu...> ;Clinical Cancer Research. 2013 Jun 1
• A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
  Berlin J, Keedy VL, Janne PA, Yee L, Rizvi NA, Jin X, Copigneaux C, Hettmann T, Beaupre DM, LoRusso P> ;J. Clin. Oncol.. 2011-05-20
• 70 citations
  Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
  Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven Reich, Ofelia Romero, Lisa M...> ;Clinical Cancer Research. 2010 Dec 1
• 7 citations
  Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a rando...
  Lee S. Schwartzberg, Ronald Burkes, Barry Mirtsching, Timothy Rearden, Peter T. Silberstein, Lorrin Yee, Amy Inamoto, Tom Lillie> ;BMC Cancer. 2010 Oct 25
• 60 citations
  A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors
  Peter Rosen, Christopher Sweeney, Dorothy J. Park, Darrin M. Beaupre, Hongjie Deng, Ian M. Leitch, Poornima Shubhakar, Min Zhu, Kelly S. Oliner, Abraham Anderson, Lorr...> ;Clinical Cancer Research. 2010 May 1
• 32 citations
  Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s...
  David I. Quinn, John Nemunaitis, Jyotsna Fuloria, Carolyn D. Britten, Nashat Gabrail, Lorrin Yee, Milin Acharya, Kai Chan, Nadine Cohen, Assen Dudov> ;Clinical Pharmacokinetics. 2009 Jan 1
• Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas.
  Mita AC, Yee LK, Papadopoulos KP, Heath EI, Romero O, Lloyd GK, Cropp G, Spear MA, Mita MM, LoRusso PM> ;J. Clin. Oncol.. 2008-05-20
• AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors.
  Rosen PJ, Sweeney CJ, Park DJ, Rasmussen E, Shubhakar P, Scripture C, Leitch I, Lu J, Beaupre DM, Yee LK> ;J. Clin. Oncol.. 2008-05-20
• 20 citations
  Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
  Julio Hajdenberg, Thomas Grote, Lorrin Yee, Roberto Arevalo-Araujo, Laurie A Latimer> ;The Journal of Supportive Oncology. 2006 Oct 1
• 24 citations
  Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000...
  Frank M. Senecal, Lorrin Yee, Nashat Y. Gabrail, Veena Charu, Dianne Tomita, Greg Rossi, Lee S. Schwartzberg> ;Clinical Breast Cancer. 2005 Dec 1
• 84 citations
  A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gyn...
  Lee S. Schwartzberg, Lorrin Yee, Frank M. Senecal, Veena Charu, Dianne Tomita, Joel F. Wallace, Greg Rossi> ;The Oncologist. 2004 Nov 1
• Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs epoetin alfa (Epo) 40,000 U weekly (QW) in anemic patients (pts) receiving chemotherapy (ctx).
  Schwartzberg L, Yee L, Senecal F, Charu V, Tomita D, Rossi G> ;J. Clin. Oncol.. 2004-07-15
• A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyelo...
  Hesketh, P.J., Arena, F., Patel, D., Austin, M., D'Avirro, P., Rossi, G., Colowick, A., Schwartzberg, L., Bertoli, L.F., Cole, J.T., Demetri, G., Dessypris, E., Dobbs,...> ;Cancer. 2004 Feb 15
• 1 citations
  N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metas...
  Jean L. Grem, Lorrin K. Yee, Barbara Schuler, J M Hamilton, Alice P. Chen, C. Chabuk, Frank Grollman, M. Grabenc, Carmen J. Allegra, Chris H. Takimoto> ;Annals of Oncology. 2001 Nov 1
• 45 citations
  High Inter- and Intrapatient Variation in 5-Fluorouracil Plasma Concentrations during a Prolonged Drug Infusion
  Chris H. Takimoto, Lorrin K. Yee, David Venzon, Barbara Schuler, Frank Grollman, Chetin Chabuk, J. Michael Hamilton, Alice P. Chen, Carmen J. Allegra, Jean L. Grem> ;Clinical Cancer Research. 1999 Jun 1
• 5 citations
  Predictive sensitivity of human cancer cells in vivo using semipermeable polysulfone fibers.
  Ming Y.W. Chu, Milton H. Lipsky, Lorrin K Yee, John Epstein, Katharine A. Whartenby, Scott M. Freeman, Tian M. Chen, Edward Chu, Edwin N. Forman, Paul Calabresi> ;Pharmacology. 1998 Jun 1
• 32 citations
  Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
  Giuseppe Pizzorno, Lorrin K. Yee, Barbara Burtness, John C. Marsh, James W. Darnowski, Ming Yu W. Chu, Shih Hsi Chu, Edward Chu, Janine J. Leffert, Robert E. Handschum...> ;Clinical Cancer Research. 1998 May 1
• 11 citations
  Inhibition of Growth Factor Mitogenicity and Growth of Tumor Cell Xenografts by a Sulfonated Distamycin A Derivative
  Paul W. Finch, Lorrin K Yee, Ming Y.W. Chu, TianM Chen, Milton H. Lipsky, Thomas Maciag, Stanley Friedman, Mel H. Epstein, Paul Calabresi> ;Pharmacology. 1997 Jul 1
• 50 citations
  Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
  Jean L. Grem, Lorrin K. Yee, David Venzon, Chris H. Takimoto, Carmen J. Allegra> ;Cancer Chemotherapy and Pharmacology. 1997 Jan 1
• 49 citations
  Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography.
  Chris H. Takimoto, Raymond W. Klecker, William L. Dahut, Lorrin K. Yee, John M. Strong, Carmen J. Allegra, Jean L. Grem> ;Journal of Chromatography. B, Biomedical Applications. 1994 Apr 22
• 40 citations
  Decreased Catabolism of Fluorouracil in Peripheral Blood Mononuclear Cells During Combination Therapy With Fluorouracil, Leucovorin, and Interferon α–2a
  Lorrin K. Yee, Carmen J. Allegra, Seth M. Steinberg, Jean L. Grem> ;Journal of the National Cancer Institute. 1992 Dec 2
• 16 citations
  Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells.
  Lorrin K. Yee, Carmen J. Allegra, Jane B. Trepel, Jean L. Grem> ;Biochemical Pharmacology. 1992 Apr 1
• Join now to see all